Photo from wikipedia
Utilization of the fetal calf serum (FCS) carries a potential health risk and raises growing economic and ethical problems. Umbilical cord blood volume reduction, required for banking, provides clinical‐grade umbilical… Click to show full abstract
Utilization of the fetal calf serum (FCS) carries a potential health risk and raises growing economic and ethical problems. Umbilical cord blood volume reduction, required for banking, provides clinical‐grade umbilical cord blood plasma (UCBP) discarded as a waste. The aim of this study was to test whether serum derived from UCBP could replace FCS for the amplification of mesenchymal stromal cells (MSCs).
Keywords:
cord blood;
calf serum;
serum;
blood volume;
fetal calf
Journal Title: Transfusion
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Transfusion
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!